Edition:
United States

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

0.74USD
1:44pm EDT
Change (% chg)

$0.00 (+0.11%)
Prev Close
$0.74
Open
$0.77
Day's High
$0.77
Day's Low
$0.72
Volume
37,937
Avg. Vol
123,494
52-wk High
$3.26
52-wk Low
$0.61

Latest Key Developments (Source: Significant Developments)

RXi Pharmaceuticals CEO Cauwenbergh buys 10,000 shares of co's common stock on Jan 19
Thursday, 19 Jan 2017 01:54pm EST 

RXi Pharmaceuticals Corp :RXi Pharmaceuticals Corp CEO Geert Cauwenbergh reports purchase of 10,000 shares of co's common stock on Jan 19 - SEC filing.  Full Article

RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc
Wednesday, 12 Oct 2016 07:02am EDT 

RXi Pharmaceuticals Corp : RXi Pharmaceuticals enters into exclusive option agreement to acquire Mirimmune Inc . RXi Pharmaceuticals Corp - can exercise option to acquire Mirimmune on terms set forth in option agreement at any time prior to April 5, 2017 . RXi Pharmaceuticals Corp - deal for number of shares equal to 19.99% of then outstanding shares of common stock of RXi . RXi Pharmaceuticals Corp - entered into an option agreement to acquire all outstanding capital stock of Mirimmune Inc .RXi Pharmaceuticals Corp - deal also provides for additional potential consideration contingent on Mirimmune reaching certain milestones.  Full Article

RXI Pharmaceuticals Qtrly loss per share $0.34
Thursday, 11 Aug 2016 07:02am EDT 

RXI Pharmaceuticals Corp : RXI Pharmaceuticals reports second quarter 2016 financial results and highlights recent corporate developments .Net revenue for quarter ended june 30, 2016 was $9,000 as compared with no revenues for quarter ended june 30, 2015.  Full Article

Rxi Pharmaceuticals reports Q1 loss of $0.34 per share
Thursday, 12 May 2016 07:40am EDT 

Rxi Pharmaceuticals Corp : Qtrly loss per share $0.34 . Believes existing cash, cash equivalents and short-term investments should be sufficient to fund operations for at least one year .Rxi pharmaceuticals reports first quarter 2016 financial results and highlights recent corporate developments.  Full Article

RXi Pharmaceuticals announces positive results with RNAi platform
Tuesday, 20 Oct 2015 07:02am EDT 

RXi Pharmaceuticals:Announces positive results with RNAi platform.Says potent reduction of long non-coding rnas demonstrated in collaboration with Biogazelle.Says considering Rxi's self-delivering platform for therapeutic applications in the future.  Full Article

RXi Pharmaceuticals reports positive interim results in mid-stage dermatology program with Rxi-109
Thursday, 15 Oct 2015 07:02am EDT 

RXi Pharmaceuticals:Reports positive interim results in mid-stage dermatology program with Rxi-109.Says both dose levels of Rxi-109 were equally well tolerated.  Full Article

RXI Pharmaceuticals granted patent in china for lead clinical candidate rxi-109
Monday, 28 Sep 2015 07:04am EDT 

RXi Pharmaceuticals Corporation:Announced that it has been granted a patent from the State Intellectual Property Office of the People's Republic of China (SIPO).For the composition and methods of use for RXI-109 and other connective tissue growth factor (CTGF) targeting self-delivering RNAi compounds (sd-rxRNA®) for the treatment of fibrotic disorders, including skin fibrosis.Patent is scheduled to expire in 2031.  Full Article

RXi Pharmaceuticals announces $10 mln public offering of common stock and warrants
Thursday, 28 May 2015 07:00am EDT 

RXi Pharmaceuticals Corp:Says pricing of a public offering of 26 mln units at a price to the public of $0.40 per share for gross proceeds of about $10.4 mln.Each unit consists of (i) one share of common stock, (ii) a 13-month overallotment purchase right to purchase 0.50 of a share of common stock at a price of $0.455 per share and (iii) a five-year warrant to purchase 0.50 of a share of common stock at a price of $0.52 per share.Offering is expected to close on or about June 2.H.C. Wainwright & Co., LLC is acting as the company's exclusive placement agent on a best efforts basis with respect to the offering.  Full Article

RXi Pharmaceuticals Corp announces proposed public offering of common stock and warrants
Wednesday, 27 May 2015 04:10pm EDT 

RXi Pharmaceuticals Corp:Commenced a public offering of shares of its common stock, warrants to purchase shares of its common stock and overallotment purchase rights to purchase shares of its common stock.Intends to use the net proceeds from this offering for general corporate purposes.  Full Article

RXi Pharmaceuticals Corp receives Orphan Drug Designation for Samcyprone from FDA for treatment of Malignant Melanoma Stage IIb to IV
Friday, 17 Apr 2015 07:50am EDT 

RXi Pharmaceuticals Corp:Announces U.S. Food and Drug Administration (FDA) grants Orphan Drug Designation of it's second clinical candidate, Samcyprone, for treatment of Malignant Melanoma Stage IIb to IV. A number of patients with Stage IIb to IV malignant melanoma develop cutaneous metastases.Samcyprone is being developed for treatment of these metastases.  Full Article

More From Around the Web